List of Excipients in Branded Drug ALKERAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ApoPharma USA Inc	ALKERAN	melphalan	52609-0001	CROSPOVIDONE
ApoPharma USA Inc	ALKERAN	melphalan	52609-0001	HYPROMELLOSE
ApoPharma USA Inc	ALKERAN	melphalan	52609-0001	MAGNESIUM STEARATE

Alkeran Excipient Strategy and Commercial Opportunities for Melphalan

Last updated: September 5, 2026

Alkeran is a legacy melphalan brand with limited remaining exclusivity value and meaningful formulation opportunities. The commercial case is strongest in injectable melphalan, where reconstitution, stability, occupational handling, cold-chain requirements, and preparation time create opportunities for differentiated products. Oral melphalan offers a smaller opportunity centered on dose flexibility, content uniformity, supply reliability, and global-market access.

What is Alkeran and which melphalan formulations are commercially relevant?

Alkeran is the branded product for melphalan, an alkylating agent used in multiple myeloma and certain ovarian cancer treatment regimens. The product has been marketed in oral tablet and intravenous powder-for-reconstitution forms.

Product	Active ingredient	Typical strength	Dosage form	Commercial relevance
Alkeran tablets	Melphalan	2 mg	Immediate-release tablet	Limited; low-dose oral oncology niche
Alkeran for Injection	Melphalan hydrochloride	50 mg per vial	Sterile powder for reconstitution	Higher opportunity because of preparation and stability constraints
Generic melphalan injection	Melphalan hydrochloride	Commonly 50 mg per vial	Sterile powder for reconstitution	Primary competitive market
Generic melphalan tablets	Melphalan	Commonly 2 mg	Immediate-release tablet	Fragmented, supply-sensitive market
Pepaxto	Melphalan flufenamide	20 mg, 40 mg	Intravenous infusion	Separate molecule and patent estate; not an Alkeran substitute in all indications

The injectable product is supplied as a sterile lyophilized or powdered drug product that requires reconstitution before dilution and administration. The oral product is a conventional immediate-release tablet. These products have different excipient, regulatory, and patent strategies.

What excipients are used in Alkeran for Injection?

The Alkeran injection presentation uses a reconstitution system containing excipients selected to address melphalan’s solubility and stability limitations.

The labeled diluent contains sodium citrate, propylene glycol, ethanol, and water for injection. The vial contains melphalan hydrochloride and formulation components associated with the sterile powder presentation. The reconstituted solution must be used within a limited period because melphalan undergoes degradation in aqueous solution, particularly as temperature increases. The prescribing information directs controlled handling and prompt use after preparation (U.S. Food and Drug Administration [FDA], n.d.-a).

Excipient or component	Functional role	Commercial implication
Sodium citrate	Buffering and pH control	May affect solubility, degradation rate, and compatibility
Propylene glycol	Cosolvent	Supports solubilization but creates tolerability and handling considerations
Ethanol	Cosolvent	Helps maintain solubility; may create labeling and handling constraints
Water for injection	Diluent	Required for sterile reconstitution
Nitrogen or inert headspace, where used	Oxidation control	May support stability during storage
Lyophilization matrix, where applicable	Cake formation and physical stability	Can affect reconstitution time and vial performance

The key formulation problem is that melphalan has limited aqueous stability. A product that reduces reconstitution delay, improves solution stability, or removes volatile organic cosolvents could command value even without changing the active ingredient.

What excipients are used in Alkeran tablets?

Alkeran tablets use standard immediate-release tablet excipients. Public product information identifies common components such as lactose, microcrystalline cellulose, povidone, crospovidone, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, hypromellose, talc, and titanium dioxide, depending on the marketed jurisdiction and presentation.

The tablet strategy is conventional. Its main development issues are content uniformity at the low 2 mg strength, chemical stability, dissolution, moisture protection, and safe handling of a cytotoxic active ingredient. A generic manufacturer must also control occupational exposure during blending, compression, coating, packaging, and cleaning.

What excipient strategies could differentiate a new melphalan product?

The most valuable strategies address injectable usability and stability rather than cosmetic tablet changes.

Ready-to-use or ready-to-dilute injection

A ready-to-use or ready-to-dilute melphalan product could eliminate or reduce bedside reconstitution. Potential formats include:

• A liquid vial with enhanced pH and cosolvent control
• A dual-chamber vial or syringe
• A cartridge-based preparation system
• A concentrated solution for dilution into an infusion bag
• A more rapidly reconstituting lyophilized cake

The principal technical barrier is maintaining melphalan stability at commercially useful concentration and temperature. A liquid product may require a narrow pH range, oxygen control, light protection, specialized container closure, or low-temperature storage.

Reduced-cosolvent formulation

Propylene glycol and ethanol support solubility but add formulation complexity. A reduced-cosolvent product could improve handling, reduce exposure concerns, and simplify pharmacy preparation. Possible approaches include:

• Alternative buffer systems
• Sulfobutylether-beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin
• Surfactant-assisted solubilization
• Mixed aqueous-organic systems with lower volatile-solvent content
• Nanoparticle or amorphous solid-dispersion approaches

These approaches require close control of extractables, container compatibility, osmolality, infusion compatibility, and toxicity. Excipients used in parenteral oncology products must have an established safety profile or a defensible regulatory qualification path.

Improved lyophilized powder

A better lyophilized product could provide shorter reconstitution time, lower foaming, improved cake integrity, and longer in-use stability. Development variables include:

• Bulking agents such as mannitol or glycine
• Stabilizers such as sucrose or trehalose
• Buffer selection and concentration
• Residual moisture
• Reconstitution volume
• Vial size and stopper design
• Protection from light and oxygen

A formulation patent can be stronger when it links a defined excipient range to measurable technical effects, such as reduced degradation products, faster reconstitution, or improved room-temperature stability.

Safer oral tablet platform

For oral melphalan, a commercial formulation can focus on:

• Improved low-dose content uniformity
• Reduced tablet weight
• Moisture-protective packaging
• Unit-dose blister packaging
• Modified manufacturing controls for cytotoxic containment
• Alternative lactose-free or low-lactose compositions
• Pediatric or dose-flexible formats, where clinically justified

A smaller tablet strength or dispersible format could address dose adjustment, although clinical and handling requirements limit the opportunity.

How does an excipient patent protect a melphalan product?

An excipient patent can protect a composition, manufacturing process, container system, or use of a formulation. The most defensible claims generally combine:

1. Melphalan or melphalan hydrochloride.
2. A defined solvent, buffer, stabilizer, or surfactant system.
3. Concentration and pH ranges.
4. A specified dosage form.
5. A stability or performance result.
6. A defined storage or reconstitution condition.

A broad claim to “melphalan with an excipient” is vulnerable to prior-art challenges. Stronger claims identify a narrow formulation window that produces a non-obvious result.

What formulation patents are likely to matter?

The relevant patent families would typically cover:

• Stable liquid melphalan compositions
• Lyophilized melphalan hydrochloride
• Low-cosolvent injectable formulations
• Container-closure systems that limit degradation
• Extended post-reconstitution stability
• Ready-to-use infusion products
• Oral solid dosage forms with improved stability or content uniformity
• Manufacturing processes that reduce impurities or control particle size

Patent applicants should file composition, process, container, and use claims in parallel. A formulation-only estate may not block a conventional generic powder if the generic does not practice the claimed excipient combination.

When does Alkeran lose exclusivity and what is the Orange Book status?

Alkeran is an older small-molecule product. Its original composition and basic product patents have expired or are no longer the primary commercial barrier in the United States. The market is therefore driven by abbreviated new drug application approval, manufacturing economics, supply reliability, and any surviving formulation or method-of-use rights.

The FDA Orange Book should be reviewed by product-specific NDA and dosage form because listings can differ between tablets and injection. Older Alkeran presentations may have discontinued marketing status, while generic melphalan products may remain approved. FDA listing status does not itself establish that a product is commercially available at any given time (FDA, n.d.-b).

Exclusivity category	Alkeran assessment
New chemical entity exclusivity	Expired
Basic composition patent	Expired or commercially immaterial
Orphan exclusivity	Not a current barrier for the legacy brand
Pediatric exclusivity	No known current commercial significance
Injectable formulation exclusivity	Requires product-specific Orange Book review
Oral formulation exclusivity	Requires product-specific Orange Book review
Biosimilar exclusivity	Not applicable
Generic pathway	ANDA pathway for qualifying products

Are Paragraph IV challenges relevant to Alkeran?

Paragraph IV risk is relevant primarily to any unexpired listed patent associated with a currently approved reference product. For a legacy product such as Alkeran, the practical risk is more likely to arise from a new formulation patent than from the original Alkeran estate.

A generic applicant could certify that a listed patent is invalid, unenforceable, or not infringed. The brand or patent owner could then bring Hatch-Waxman litigation within the statutory period, potentially triggering a stay of approval. The commercial value of a Paragraph IV case depends on whether the challenged patent covers the reference product itself or only a narrow formulation.

For a new melphalan product, the risk profile is different. A later entrant could challenge formulation patents after approval, while the innovator could rely on multiple overlapping claims to delay substitution or preserve a premium presentation.

What patent litigation and settlement issues affect melphalan?

No major current Alkeran litigation should be assumed without a live review of FDA, PACER, district court, and appellate records. The legacy product’s principal commercial question is usually whether an active, Orange Book-listed patent remains enforceable for the specific dosage form.

Settlement agreements in this area would be relevant if they include:

• An agreed generic launch date
• A license to a formulation patent
• Restrictions on manufacturing or distribution
• A supply agreement
• Authorized-generic rights
• Allocation of injectable capacity
• Confidentiality or patent-challenge terms

For diligence, settlement analysis should distinguish Alkeran from Pepaxto. Pepaxto contains melphalan flufenamide, a different compound with a separate clinical, regulatory, and patent profile.

What FDA regulatory pathway applies to a new melphalan product?

A conventional generic tablet or injectable powder would generally use the ANDA pathway if the applicant can demonstrate pharmaceutical equivalence and bioequivalence or meet applicable product-specific requirements. A materially different formulation may require a 505(b)(2) application.

Product concept	Likely pathway	Main regulatory burden
Conventional 2 mg tablet	ANDA	Bioequivalence, dissolution, CMC, cytotoxic controls
Conventional 50 mg powder for injection	ANDA	Sterility, potency, impurities, reconstitution, stability
Ready-to-use liquid injection	505(b)(2) or other applicable pathway	New formulation safety, stability, compatibility, clinical bridging
New delivery device	505(b)(2), with device review	Device performance and human factors
Modified-release oral product	505(b)(2)	Pharmacokinetics and clinical justification
New indication	505(b)(2) or supplemental application	Clinical efficacy and safety evidence

FDA review will focus heavily on degradation products, sterility assurance, particulate matter, container closure, infusion compatibility, and occupational controls. The product’s cytotoxic classification raises expectations for containment and manufacturing segregation.

What commercial opportunities exist for melphalan excipients?

The strongest opportunities are in hospitals and transplant centers where staff time, preparation safety, and product wastage have measurable economic value.

Injectable opportunity

A differentiated injectable could compete on:

• Longer refrigerated or room-temperature stability
• Faster reconstitution
• Fewer preparation steps
• Lower vial wastage
• Reduced organic solvent content
• Smaller storage footprint
• Compatibility with common infusion bags and devices
• Lower exposure risk for pharmacy personnel
• More predictable supply than incumbent products

A ready-to-use product could receive a premium if it reduces pharmacy labor and discarded doses. The commercial hurdle is that melphalan is a mature, price-sensitive generic market. A premium requires documented workflow savings, lower waste, or meaningful stability advantages.

Oral opportunity

The oral market supports more modest differentiation:

• Reliable supply of 2 mg tablets
• Dose-flexible packaging
• Moisture-resistant unit doses
• International supply where branded Alkeran is unavailable
• Contract manufacturing for oncology distributors
• Specialty-pharmacy packaging
• Lower-cost products for public health systems

Manufacturers should avoid excipient changes that create unnecessary food-effect, dissolution, or bioequivalence complexity.

How strong is the Alkeran patent estate?

The legacy Alkeran patent estate is weak as a blocking platform because the core product is old and generic competition exists. A new entrant would gain more protection from a technically differentiated formulation than from relying on historical Alkeran rights.

Estate component	Relative strength	Reason
Original melphalan composition	Low	Old molecule and expired core rights
Conventional tablet	Low	Crowded formulation and generic substitution
Conventional powder injection	Low to moderate	Manufacturing and sterile controls remain barriers
Stable liquid injection	Moderate to high	Potentially differentiated technical solution
Ready-to-use presentation	Moderate to high	Combination of composition and container claims
Low-cosolvent formulation	Moderate	Strength depends on unexpected stability or tolerability data
Manufacturing process	Moderate	Can protect impurity control and scale-up methods
Device-enabled delivery	Moderate	Requires integrated formulation and device claims

Which companies are likely to compete with a new melphalan product?

Competition is likely to come from generic injectable manufacturers, specialty oncology suppliers, contract manufacturers, and distributors rather than from the Alkeran brand itself. Relevant competitive capabilities include:

• Sterile lyophilization
• Cytotoxic containment
• High-potency API handling
• Global regulatory registrations
• Hospital contracting
• Reliable injectable supply
• Controlled-substance or hazardous-drug logistics

The most important competitive advantage may be manufacturing resilience. Melphalan is a low-volume oncology product, so shortages or production interruptions can materially influence purchasing decisions.

What generic launch scenarios exist for Alkeran?

A new entrant has four practical launch scenarios.

Scenario	Product	Positioning	Main risk
Low-cost generic	Conventional tablet or powder	Price and supply	Limited margin
Supply-reliability entrant	Conventional injectable	Contract and hospital access	Commodity pricing
Workflow-improvement product	Faster-reconstituting vial	Reduced preparation burden	Requires evidence of economic value
Premium formulation	Stable liquid or ready-to-use product	Convenience and lower waste	Higher CMC and regulatory cost

The best commercial path is usually a differentiated injectable supported by formulation patents and hospital-economic data. A tablet launch can succeed where supply is constrained, but it is less likely to support durable pricing.

What geographic markets offer the best opportunity?

The United States offers the clearest regulatory and contracting framework but has strong generic price pressure. Europe and other regulated markets may reward supply continuity and hospital tender performance. Emerging markets can offer volume growth but may require local registration, temperature-stability data, lower-cost packaging, and regional manufacturing or distribution partnerships.

A global excipient strategy should account for:

• Different approved excipient limits
• Ethanol and propylene glycol labeling requirements
• Local stability zones
• Cold-chain availability
• Pharmacopoeial standards
• Cytotoxic waste rules
• Import controls
• Local tender purchasing

Key Takeaways

• Alkeran is a legacy melphalan brand with limited remaining core exclusivity value.
• The principal technical opportunity is injectable melphalan, not the conventional oral tablet.
• Sodium citrate, propylene glycol, ethanol, and water are central components of the established injectable reconstitution system.
• Ready-to-use, faster-reconstituting, lower-cosolvent, and more stable injectable products offer the strongest differentiation potential.
• A new formulation should combine composition, process, container, and use claims.
• Paragraph IV risk depends on any active product-specific Orange Book patent, not on historical Alkeran rights.
• Biosimilar competition is not relevant because melphalan is a small molecule.
• Commercial success will depend on stability, pharmacy workflow, product waste, supply reliability, and hospital economics.
• The strongest generic launch strategy is a differentiated injectable supported by measurable preparation or stability advantages.

FAQs About Alkeran Excipient Strategy and Commercial Opportunities

Can propylene glycol be removed from melphalan injection?

It may be possible, but removal would require a replacement solubilization and stability system. The reformulated product would need new CMC, compatibility, impurity, and regulatory evidence.

Is a ready-to-use melphalan formulation patentable?

Yes, if the formulation has novel and non-obvious composition, concentration, container, stability, or reconstitution characteristics. Patent strength depends on claim scope and supporting technical data.

Does Alkeran have biosimilar risk?

No. Melphalan is a chemically synthesized small molecule. Competitive products follow generic-drug pathways rather than biosimilar pathways.

What is the most valuable excipient opportunity for melphalan?

A stable injectable formulation that reduces reconstitution steps, extends in-use stability, lowers cosolvent content, or reduces vial waste has the highest commercial potential.

Can a generic manufacturer receive exclusivity for a new melphalan formulation?

A manufacturer may obtain patent protection for a novel formulation or process. Regulatory exclusivity depends on the application type and FDA designation, while patent protection depends on claim validity and infringement.

References

1. U.S. Food and Drug Administration. (n.d.-a). Alkeran (melphalan hydrochloride) for injection prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/

3. National Library of Medicine. (n.d.). DailyMed: Melphalan hydrochloride injection and melphalan tablets labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

4. U.S. Food and Drug Administration. (2019). M9 biopharmaceutics classification system-based biowaivers guidance for industry. FDA.

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.